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The pathogenicity of Mycobacterium ulcerans, the agent of Buruli ulcer, depends on the cytotoxic exotoxin
mycolactone. Little is known about the immune response to this pathogen. Following the demonstration of an
intracellular growth phase in the life cycle of M. ulcerans, we investigated the production of tumor necrosis
factor (TNF) induced by intramacrophage bacilli of diverse toxigenesis/virulence, as well as the biological
relevance of TNF during M. ulcerans experimental infections. Our data show that murine bone marrow-derived
macrophages infected with mycolactone-negative strains of M. ulcerans (nonvirulent) produce high amounts of
TNF, while macrophages infected with mycolactone-positive strains of intermediate or high virulence produce
intermediate or low amounts of TNF, respectively. These results are in accordance with the finding that TNF
receptor P55-deficient (TNF-P55 KO) mice are not more susceptible than wild-type mice to infection by the
highly virulent strains but are more susceptible to nonvirulent and intermediately virulent strains, demon-
strating that TNF is required to control the proliferation of these strains in animals experimentally infected
by M. ulcerans. We also show that mycolactone produced by intramacrophage M. ulcerans bacilli inhibits, in a
dose-dependent manner, but does not abrogate, the production of macrophage inflammatory protein 2, which
is consistent with the persistent inflammatory responses observed in experimentally infected mice.
Mycobacterium ulcerans is the etiological agent of Buruli
ulcer (BU), a devastating, necrotizing skin disease that has
increased dramatically over the past decade and has become
the third most common mycobacterial infection in humans,
after tuberculosis and leprosy (15, 85). In some African trop-
ical areas, the number of BU cases may even exceed those of
tuberculosis and leprosy (16, 86). BU has a huge socioeco-
nomic impact in the affected populations and represents an
important public health issue in terms of morbidity, treatment,
and functional disabilities (3). In addition to the increase in the
actual number of cases, there has also been an increasing
geographical spread of BU within some tropical countries (86).
Mycobacteria have developed several mechanisms to avoid
the harmful effects of the host immune response, including the
secretion of soluble factors that have cytotoxic activity against
the host cells, the impairment of the bactericidal activity of
macrophages, or the modulation of the immune response. My-
cobacterium tuberculosis, a mycobacterium closely related to M.
ulcerans (83), secretes culture filtrate protein 10, early secre-
tory antigen target 6, and Man-LAM that exhibit cytotoxic
activities against the infected cells or inhibit the production of
macrophage-activating cytokines, such as tumor necrosis factor
(TNF) (29, 45, 51, 77, 81). Furthermore, it has been suggested
that M. tuberculosis induces an increased production of inter-
leukin-10 (IL-10), a cytokine with immunosuppressive activity
(34). M. ulcerans also exhibits cytotoxic activity (32, 50, 56, 67).
However, unlike M. tuberculosis, M. ulcerans cytotoxicity is pri-
marily associated with the production of a unique polyketide lipid
exotoxin, mycolactone (32, 33). The genetic basis for mycolac-
tone production was elucidated with the discovery of a giant
plasmid that carries all the genes required for mycolactone
production (80). It is also known that M. ulcerans isolates from
different geographical origins produce diverse types of myco-
lactones (56). The African strains produce mainly mycolac-
tones A/B, whereas Australian strains produce mainly myco-
lactone C (56). These mycolactones are very similar, with the
exception that mycolactone C has one less hydroxyl group on
C-12 of the fatty acid side chain (46, 79). Despite this sole
difference between mycolactones A/B and C, the latter has
been shown to be less cytopathic (46, 56). The different profiles
in mycolactone production might contribute to the lower se-
verity of BU disease observed in Australia compared to that in
Africa (46). However, it cannot be excluded that production of
different amounts of mycolactone may also account for the
different degrees of virulence among M. ulcerans strains.
In the mouse fibroblast L929 cell line, mycolactone has a
cytopathic effect characterized by cell cycle arrest, cell round-
ing, detachment from the monolayer and, ultimately, apoptosis
(31–33, 56). Injection of mycolactone in the guinea pig skin
or infection with wild-type (WT) mycolactone-producing M.
ulcerans induces the formation of ulcers, while infection with a
mycolactone-negative mutant strain fails to induce ulceration
in this animal model (32). The pathology of M. ulcerans infec-
tions is therefore closely associated with the secretion of this
exotoxin, which is primarily responsible for the extensive ne-
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crosis that characterizes BU. Additionally, it has been shown
that mycolactone inhibits TNF production (60).
TNF is an effector cytokine produced mainly by macro-
phages and has an autocrine effect on the activation of the
macrophage’s microbicidal activity against intracellular para-
sites, including Listeria monocytogenes (39), M. tuberculosis (17,
26), Mycobacterium bovis BCG (48), and some strains of My-
cobacterium avium (69). TNF is, therefore, critical for both the
antibacterial and the inflammatory host responses against my-
cobacteria (25). TNF and other cytokines and chemokines
produced by macrophages, such as IL-6, IL-1, and macrophage
inflammatory protein 2 (MIP-2) (the murine homologue of
human IL-8), have an impact on the recruitment of inflamma-
tory cells (5, 18), as well as on the activation and phenotype of
T cells (61, 73).
It has been recently shown that M. ulcerans has an intra-
macrophage growth phase (84), which is in accordance with the
occurrence of cell-mediated immunity and delayed-type hyper-
sensitivity responses in BU patients (20, 35, 36, 40, 41, 49, 53,
54, 58, 64, 66, 76, 78, 82, 86, 87). The correlation between the
amounts of TNF produced by macrophages infected with dif-
ferent strains of M. ulcerans and the mycolactones produced by
these strains, as well as the biological relevance of TNF in the
progression of infection by M. ulcerans, is currently unknown.
A previous report showed that a lipidic fraction of M. ulcerans
culture filtrates containing mycolactone suppressed in vitro the
production of TNF by human monocytes (60). On the other
hand, the expression of TNF is detected in high concentrations
in the lesions of BU patients (66). Furthermore, TNF is known
to participate in the formation of granulomas (25), which in
BU has been shown to occur during the healing phase of the
disease (1, 40, 41, 78, 86).
Taking these data into consideration, it is important to study
the effects of infection with different strains of M. ulcerans
on the cytokine production by macrophages, as well as to assess
the role of TNF in M. ulcerans infection in vivo. A panel of
strains of M. ulcerans that produce different types of mycolac-
tone or that are mycolactone negative was used in the present
work in order to characterize the production of both the proin-
flammatory cytokine TNF and the chemokine MIP-2 by in-
fected bone marrow-derived macrophages (BMDM). In addi-
tion, the biological relevance of TNF production in vivo was
assessed by using TNF receptor P55-deficient (TNF-P55 KO)
mice infected with different strains of M. ulcerans. To further
dissect the role of mycolactone on the production of TNF by
M. ulcerans-infected macrophages, we compared WT M. ulcer-
ans with isogenic mutants in which the mycolactone genes were
deleted or interrupted by transposon insertion.
We found that BMDM infected with highly virulent but not
with intermediately virulent or nonvirulent strains of M. ulcer-
ans produced low levels of TNF. In addition, we show that
mycolactone inhibits TNF production, in a dose-dependent
manner. Interestingly, MIP-2 production was decreased but
not abrogated, even in macrophages infected with highly viru-
lent strains. Finally, our data show that TNF induced during M.
ulcerans infection plays a protective role.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The M. ulcerans strains used in this
study were selected based on their geographical origin and on the type of
mycolactone produced (Table 1). Strain 97-1116 is an isolate from Benin that
produces a mycolactone A/B that is characteristic of African strains (57). Strain
98-912 was isolated from a Chinese patient and produces a mycolactone A/B
slightly different from those in African strains (44). Strain 94-1327 is an isolate
from Australia and produces the characteristic mycolactone C (56); its plasmid
lacks the gene MUP053 encoding a P450 hydroxylase required to hydroxylate the
mycolactone side chain at C-12 to produce mycolactone A/B (79). Strain 94-1331
is an isolate from Papua New Guinea that is similar to the mycolactone C-
producing Australian strains in the sense that its plasmid also lacks the gene
MUP053 that is necessary for mycolactone A/B production (79), although it was
suggested that this strain can also produce mycolactone A/B (43). Strain 5114 is
an isolate from Mexico and does not produce mycolactone (56) due to the loss
of key genes involved in the synthesis of this macrolide (79). Mycobacterium
marinum 00-1026, obtained from a patient living in France, is closely related
genetically to M. ulcerans and was used as a negative control for mycolactone
production (8, 89). Finally, the mycolactone-defective M. ulcerans 1615A, a
spontaneous mutant, was isolated from nonpigmented colonies of M. ulcerans
1615 (32), a strain from Malaysia that produces mycolactone A/B (56). All strains
used in this work, except for strain 1615, are from the collection of the Institute
of Tropical Medicine, Antwerp, Belgium.
The isolates were grown on Löwenstein-Jensen medium at 32°C for approxi-
mately 1 month, recovered from slants, diluted in phosphate-buffered saline to a
final concentration of 1 mg/ml, and vortexed using 2-mm glass beads. The
number of acid-fast bacilli (AFB) in the inocula was determined according to the
method described by Shepard and McRae (72), using Ziehl-Neelsen staining
(Merck, Darmstadt, Germany). The final suspensions revealed more than 90%
viable cells as assessed with a LIVE/DEAD Baclight kit (Molecular Probes,
Leiden, The Netherlands).
Animals. Eight-week-old female BALB/c, C57BL/6, and TNF-P55 KO mice
were obtained from Charles River (Barcelona, Spain) and were housed under
specific-pathogen-free conditions with food and water ad libitum.
Footpad model of infection. Mice were infected in the left hind footpad with
0.03 ml of M. ulcerans suspension containing 5 log10 AFB. The right hind footpad
was used as a control.
Culture of murine BMDM. Macrophages were derived from the bone marrow
as follows: mice were sacrificed with CO2 and femurs removed under aseptic
conditions. Bones were flushed with 5 ml cold Hanks’ balanced salt solution
(HBSS; Gibco, Paisley, United Kingdom). The resulting cell suspension was
centrifuged at 500  g and resuspended in Dulbecco’s modified Eagle’s medium
(DMEM; Gibco) supplemented with 10 mM HEPES (Sigma, St. Louis, MO), 1
mM sodium pyruvate (Gibco), 10 mM glutamine (Gibco), 10% heat-inactivated
fetal bovine serum (Sigma), and 10% L929 cell conditioned medium (complete
DMEM [cDMEM]). To remove fibroblasts or differentiated macrophages, cells
were cultured for a period of 4 h on cell culture dishes (Nunc, Naperville, IL)
with cDMEM. Nonadherent cells were collected with warm HBSS, centrifuged at
500  g, distributed in 24-well plates at a density of 5  105 cells/well, and
incubated at 37°C in a 5% CO2 atmosphere. On day 4 after seeding, 0.1 ml of
L929 cell conditioned medium was added, and medium was renewed on the
seventh day. After 10 days in culture, cells were completely differentiated into
macrophages. Twelve hours before infection, macrophages were incubated at











M. ulcerans 98-912 Ulcer China 1997 A/Ba
M. ulcerans 97-1116 Plaque Benin 1997 A/B
M. ulcerans 1615 Ulcer Malaysia 1964 A/B
M. ulcerans 94-1331 NDc Papua New
Guinea
1994 A/Bb
M. ulcerans 94-1327 Ulcer Australia 1994 C
M. ulcerans 5114 Ulcer Mexico 1953 
M. marinum 00-1026 d France 2000 
a Mycolactone A/B slightly different from those in African strains (44).
b Like mycolactone C-producing Australian strains, this strain lacks the plas-
mid gene MUP053 that is involved in mycolactone A/B production (79), although
it has been suggested that it also produces mycolactone A/B (43).
c ND, not determined.
d , negative result.
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32°C in a 5% CO2 atmosphere and maintained until the end of the experimental
infection as described elsewhere (59).
Macrophage infectivity assays. Bacterial suspensions were prepared as de-
scribed above and further diluted in cDMEM before infecting macrophage
monolayers. M. ulcerans suspensions (0.2 ml) were diluted in cDMEM and added
to each well in order to obtain the multiplicity of infection (MOI) indicated for
each experiment (bacterium/macrophage ratio). Cells were incubated for 4 h at
32°C in a 5% CO2 atmosphere and then washed four times with warm HBSS to
remove noninternalized bacteria and reincubated in cDMEM for a maximum
period of 6 days. To confirm the MOI, counting of AFB in infected macrophages
was performed at the beginning of experimental infection as described previously
(72).
Mycolactone purification. After purification of mycolactone as described else-
where (32, 56), the toxin was dissolved in ethanol (100%) and stored at 4°C. The
toxin was added to cultured cells by diluting the original preparation in culture
medium (DMEM) to a maximum concentration of 0.001% of ethanol. In addi-
tion, the wells with control, noninfected macrophages were kept with the same
amount of diluted ethanol that was found to be noncytotoxic for macrophages at
this residual concentration.
Cytokine analysis by ELISA. At selected time points postinfection, macro-
phage cultures were centrifuged and the supernatants removed and stored frozen
until cytokine analysis by enzyme-linked immunosorbent assay (ELISA). TNF
and MIP-2 were measured in the culture supernatant using commercial kits
(R&D Systems, Minneapolis, MN) according to the manufacturer’s specifica-
tions.
Statistical analysis. Statistical significance of values was determined using the
Student t test.
RESULTS
Different strains of M. ulcerans exhibit diverse cytotoxicity in
vitro that correlates with mycolactone production and with
virulence for mice. It was previously shown that mycolactone
A/B-producing M. ulcerans bacilli exhibit cytotoxic activity
against infected macrophages (59), following an intramacro-
phage phase of proliferation (84). These same strains induced
progressive infections following experimental inoculation of
mouse footpads (59). On the other hand, a mycolactone-neg-
ative strain was shown to be noncytotoxic and unable to induce
lesions in infected footpads (59). In the present work, we
expanded our observations by evaluating the cytotoxic activi-
ties of a panel of M. ulcerans strains that produce diverse types
of mycolactone or are nonproducers of mycolactone, using a
model of BMDM infection at 32°C. Additionally, we investi-
gated the association between cytotoxicity and virulence for
experimentally infected mice.
Macrophages were infected at a 1:1 MOI with the mycolac-
tone-negative strain 5114 or with mycolactone-producing
strain 94-1331, 94-1327, 97-1116, or 98-912. As a control, mac-
rophages were infected with M. marinum 00-1026, which does
not produce mycolactone. The cytotoxicity of M. ulcerans was
assessed by the occurrence of the typical cytopathic changes
induced in cultured cells either by isolated mycolactone (31–
33) or by intracellular infection with mycolactone-producing
M. ulcerans bacilli (59, 84). Those cytopathic changes include
cell rounding and detachment from the monolayer followed by
cell death (31–33). The evaluation of virulence was performed
by measuring over time of the swelling of footpads infected
with 5.3 log10 AFB of M. ulcerans (59).
Confirming our previous observations (59), we found that
the M. ulcerans strains 98-912 and 97-1116, which produce
mycolactone A/B, were highly cytotoxic, inducing cell round-
ing, shrinkage, and detachment of more than 90% of cultured
macrophages at 6 days postinfection (Fig. 1A), and highly
virulent, as shown by the occurrence of footpad swelling be-
tween the second and fourth weeks following infection (Fig.
1A). In contrast, no significant alterations were found in mono-
layers infected with the noncytotoxic, mycolactone-negative
strain 5114 or with M. marinum 00-1026 (Fig. 1C), which also
did not induce measurable footpad swelling up to 25 weeks
FIG. 1. Cytotoxic activity and virulence of different strains of M.
ulcerans. (Left) BMDM were infected with different strains of M.
ulcerans at an MOI (bacilli/macrophages) of 1:1. Macrophages were
photographed by phase-contrast microscopy 6 days after infection. M.
ulcerans cytotoxicity was determined based on the microscopic obser-
vation of cell rounding and detachment from the monolayer. (Right)
Mice were infected in the left hind footpad with 5.3 log10 AFB of
different M. ulcerans strains. Virulence was determined by measuring
footpad swelling. For ethical reasons mice were sacrificed after the
emergence of ulceration. Results are from one representative experi-
ment out of three independent experiments.
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postinfection (Fig. 1C). The Australian mycolactone C-pro-
ducing strain, M. ulcerans 94-1327, showed intermediate cyto-
toxic activity in vitro and intermediate virulence for mice (Fig.
1B). Interestingly, strain 94-1331 from Papua New Guinea,
which, like Australian strains, lacks the gene MUP053 that
encodes the P450 hydroxylase necessary to hydroxylate C-12 to
form mycolactone A/B, also showed an intermediate pattern of
in vitro cytotoxicity and virulence (Fig. 1B).
These results confirm the importance of mycolactone as the
key pathogenic factor of M. ulcerans, showing a correlation
between mycolactone production and cytotoxic activity for
infected cells and virulence for the host.
BMDM infected with strains of M. ulcerans of diverse cyto-
toxicity/virulence produce different amounts of TNF. Macro-
phages are key elements in the immune response against in-
tracellular parasites. It is known that among other factors, the
autocrine activity of TNF on infected macrophages is critical to
control the proliferation of the intracellular mycobacterium M.
tuberculosis (17, 26) and M. avium (69). It was recently shown
that M. ulcerans has a phase of intramacrophage residence and
proliferation before it induces the mycolactone-dependent ly-
sis of infected host cells (84). It is therefore important to study
the production of TNF by macrophages infected with different
clinical isolates of M. ulcerans.
Following the characterization of cytotoxicity/virulence of
the panel of M. ulcerans strains, we found that infection of
BMDM at a 1:1 MOI with those strains led to the production
of different amounts of TNF. TNF production was highest in
BMDM infected with the mycolactone-negative, nonvirulent
strain 5114 or M. marinum 00-1026. In cells infected with
highly cytotoxic/virulent strains that produce mycolactone type
A/B, TNF levels were lower than 100 pg/ml (Fig. 2). Accord-
ingly, TNF production by strains of M. ulcerans of intermediate
cytotoxicity/virulence was intermediate (Fig. 2). To investigate
if the reduced production of TNF by macrophages infected
with mycolactone A/B-producing M. ulcerans strains was asso-
ciated with a decreased production of other macrophage-de-
rived proinflammatory cytokines, we evaluated the expression
of IL-1 and IL-6. Expression of high amounts of both cytokines
occurred in BMDM infected with the mycolactone-negative
strain 5114 but not with the mycolactone A/B-producing strain
98-912 (data not shown).
These results show that the production of proinflammatory
cytokines such as TNF by BMDM infected with M. ulcerans is
dependent on the strain’s mycolactone-associated toxicity.
The reduced production of TNF by BMDM infected with
mycolactone A/B-producing strains is not related to an early
cytotoxic effect or to cell death. It has been previously shown
that at high MOI, mycolactone-producing M. ulcerans strains
exhibit an early cytotoxic effect on cultured cells (13, 84).
However, the damage to monolayers was found to be pre-
vented when the experimental infection was performed at a
low MOI (84).
To evaluate if the inhibition of TNF production by the my-
colactone A/B-producing strains was due to an early cytotoxic
effect on BMDM, monolayers were infected with different
MOIs of M. ulcerans 98-912 or M. ulcerans 5114, as a control.
As shown in Fig. 3A, production of high amounts of TNF was
found at high MOIs in macrophages infected with M. ulcerans
FIG. 2. TNF production by BMDM infected with strains of M.
ulcerans that produce different amounts and types of mycolactone.
Strains of M. ulcerans from different origins were used to infect
BMDM at an MOI of 1:1. At days 2, 4, and 6 postinfection the
supernatants of three independent wells were removed for each strain
and frozen until cytokine measurement by ELISA. Low amounts of
TNF were produced by macrophages infected with high cytotoxic/
virulent strains (98-912 and 97-1116), whereas high amounts of TNF
were produced in the case of the low cytotoxicity/low virulence strain
5114 or M. marinum 00-1026. Intermediate levels of TNF are produced
with strains of intermediate cytotoxicity/virulence (94-1327 and 94-
1331). Error bars indicate standard deviations. Results are from one
representative experiment out of three independent experiments.
FIG. 3. TNF production by BMDM infected at different MOIs with
the mycolactone A/B-producing strain 98-912 or the mycolactone-
negative strain 5114. BMDM were infected at MOIs ranging from 10:1
to 1:15 with the M. ulcerans strains 5114 (A) or 98-912 (B). Twenty-
four hours postinfection, the supernatant from three independent
wells was removed for each strain and stored frozen until cytokine
measurement by ELISA. BMDM infected with M. ulcerans 5114 pro-
duce high amounts of TNF at high MOIs, and TNF production de-
creases as the MOI decreases. With M. ulcerans 98-912, production of
TNF is low, independent of the MOI. Results are from one represen-
tative experiment out of three independent experiments.
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5114, which diminished as the mycobacterium/macrophage ra-
tio decreased. In contrast, infection with strain 98-912 was not
associated with high amounts of TNF production by macro-
phages, even at a very low MOI (Fig. 3B), for which cytotoxic
activity was not observed (data not shown). Additionally, we
did not find significant levels of apoptosis in infected macro-
phages 24 h after infection and macrophages were metaboli-
cally active, since they could phagocytose latex beads (data not
shown). These results suggest that the very low production of
TNF by BMDM infected with the highly virulent strain M.
ulcerans 98-912 is not associated with an early death of mac-
rophages but possibly to an inhibitory effect of mycolactone.
Addition of mycolactone A/B to BMDM infected with a my-
colactone-defective strain inhibits or completely suppresses
the production of TNF in a dose-dependent manner. To ad-
dress the contribution of mycolactone to the inhibition of TNF
production by M. ulcerans-infected BMDM, we performed ex-
periments using isogenic strains: the WT, mycolactone A/B-
producing strain M. ulcerans 1615, which is virulent for mice
(13), and the isogenic mycolactone-deficient, nonvirulent
strain, M. ulcerans 1615A (32).
In Fig. 4A, we show that, as previously found for the myco-
lactone-negative strain 5114 (Fig. 2 and 3), high levels of TNF
were produced by macrophages infected with the mycolactone-
defective strain 1615A compared to WT, mycolactone-positive
M. ulcerans. The high levels of TNF produced by macrophages
infected with the mutant strain were particularly significant for
MOIs of 1:1 or higher (Fig. 4B). On the contrary, much lower
amounts of TNF were produced by macrophages infected with
WT M. ulcerans 1615 at high MOI (Fig. 4C). In fact, for a 1:1
MOI, the reduction of the amount of TNF produced was
4.5-fold, but at an MOI of 5:1 the reduction was 33-fold,
comparing the WT with the mutant strain. These results
strongly suggest that mycolactone plays a major role in the
inhibition of TNF production by M. ulcerans-infected BMDM
in a dose-dependent manner. To confirm if this inhibitory
effect was in fact mycolactone dependent, we infected BMDM
with M. ulcerans 1615A in the presence of different amounts of
mycolactone A/B. Figure 4D shows that the addition of myco-
lactone inhibited the TNF production induced by the M. ulcer-
ans mutant strain in a dose-dependent manner. The addition
of 5 ng of mycolactone, the minimal dose tested, reduced
significantly the production of TNF, and the highest dose
tested (50 ng) abrogated the production of this cytokine (Fig.
4D).
Overall, these results demonstrate that mycolactone plays a
major role in the inhibition of TNF production by BMDM
infected with virulent M. ulcerans.
Addition of mycolactone A/B to BMDM infected with a my-
colactone-defective strain moderates the production of MIP-2
in a dose-dependent manner but does not abrogate its produc-
tion. In contrast with previous descriptions, recent results de-
scribed inflammatory responses with infiltration of neutrophils
and mononuclear cells in a high percentage of cases of M.
ulcerans infection in humans (38, 84). In addition, it was shown
in the mouse model that M. ulcerans infection induces a per-
sistent inflammatory response, with the recruitment of neutro-
phils and macrophages to the infection focus (59). We hypoth-
esized that the recruitment of inflammatory cells in response to
infections by M. ulcerans strains associated with low levels of
FIG. 4. TNF production by BMDM infected with WT M. ulcerans
1615 or with the mycolactone-defective mutant 1615A: kinetics and effects
of MOI and supplementation with mycolactone. BMDM were infected
with a 1:1 MOI (A and D) or at different MOIs ranging from 10:1 to 1:15
(B and C) with M. ulcerans 1615A or 1615 WT, in the presence (D) or
absence (A to C) of mycolactone. For cytokine measurement by ELISA,
supernatants of three independent wells were collected from each exper-
imental group. (A) Higher amounts of TNF are produced with infection
by M. ulcerans 1615A in comparison to M. ulcerans 1615. (B and C)
BMDM infected with M. ulcerans 1615A produce large amounts of TNF
at high MOIs, and that production declines as the MOI is decreased. M.
ulcerans 1615 induces the production of smaller amounts of TNF peaking
at low MOI. (D) Addition of mycolactone to M. ulcerans 1615A-infected
macrophages diminishes or abrogates the production of TNF. TNF was
not detected in the presence of 50 ng mycolactone. Results are from one
representative experiment out of two independent experiments.
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TNF production could be mediated by macrophage-derived
chemokines, such as MIP-2. MIP-2 is a chemokine associated
with the recruitment of neutrophils and is produced mainly by
macrophages (88).
To address this point, we measured the production of MIP-2
following the infection of BMDM with M. ulcerans 1615 or
1615A. As shown in Fig. 5A, we found a relevant production of
MIP-2 by BMDM infected at a 1:1 MOI, with either strain,
although with higher values for the mycolactone-defective
strain. For low MOIs, both M. ulcerans 1615 as well as the
mutant strain defective in mycolactone induced the production
of high levels of MIP-2 (Fig. 5B and C). In BMDM infected
with the WT strain, low levels of MIP-2 production were only
found at high MOIs (Fig. 5C). In fact, at 1:1 and 1:5 MOIs, the
reduction of MIP-2 production by BMDM infected with M.
ulcerans 1615 was 2.2- and 1.3-fold, respectively, compared to
the strain defective in mycolactone. Accordingly, the addition
of increasing amounts of mycolactone to BMDM cultures only
induced a moderate decrease in the production of MIP-2 (Fig.
5D), compared to the effect reported above for TNF produc-
tion (Fig. 4C). Moreover, this chemokine was still produced in
relevant amounts after the addition of the maximal dose of
mycolactone tested.
Overall, these results show that the infection of macro-
phages with a virulent strain of M. ulcerans induces the pro-
duction of important amounts of MIP-2, even at a high MOI,
which is in accordance with the occurrence of the inflammatory
responses observed in BU patients and experimentally infected
mice.
TNF plays a role in the control of infections by M. ulcerans.
Studies in the mouse model have shown that TNF is a critical
cytokine for protective immune responses against M. tubercu-
losis (25). This cytokine has been reported to be produced in
BU lesions (64, 66); however, its biological relevance following
M. ulcerans infection is not known.
Following the characterization of TNF production by mac-
rophages infected with M. ulcerans, we tested the biological
role of this cytokine in an experimental model of BU. WT or
TNF-P55 KO mice were infected with different strains of M.
ulcerans. The proliferation of mycobacteria in the infected
footpads was monitored for a period of 3 months. The growth
of strain 5114, which was found to be a strong inducer of TNF,
was hindered in vivo by WT mice but not by TNF-P55 KO mice
(Fig. 6). For this M. ulcerans strain, the increase in the bacterial
proliferation between TNF-P55 KO and WT mice was of 0.8
log10 over an 85-day period. In contrast, M. ulcerans 98-912,
which is not associated with the production of relevant
amounts of TNF in vitro, showed similar patterns of mycobac-
terial proliferation in both mouse strains, before the emer-
gence of ulceration (Fig. 6). Interestingly, we found an inter-
mediate increase of 0.5 log10 in bacterial counts, at day 40
postinfection, between TNF-P55 KO and WT mice infected
with strain 94-1327 (Fig. 6), for which an intermediate produc-
tion of TNF was seen in vitro, as shown above (Fig. 2).
FIG. 5. MIP-2 production by BMDM infected with WT M. ulcerans
1615 or with the mycolactone-defective mutant 1615A: kinetics and
effects of MOI and supplementation with mycolactone. BMDM were
infected with a 1:1 MOI (A and D) or with MOIs ranging from 10:1 to
1:15 (B and C) of M. ulcerans strain 1615A or 1615, in the presence
(D) or absence (A to C) of mycolactone. For cytokine measurement by
ELISA, supernatants of three independent wells were collected from
each experimental group. (A) Although M. ulcerans 1615A induces
larger amounts of MIP-2 in comparison with M. ulcerans 1615, signif-
icant amounts of the cytokine are produced with the mycolactone-
positive strain. (B and C) BMDM infected with M. ulcerans 1615A
produce large amounts of MIP-2 irrespective of MOI. M. ulcerans 1615
induces the production of small but important amounts of MIP-2 at
low MOIs. (D) Addition of mycolactone to M. ulcerans 1615A-infected
macrophages diminishes but does not abrogate the production of
MIP-2, even at high concentrations. Results are from one representa-
tive experiment out of two independent experiments.
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Overall, these results show that TNF plays a protective role
in M. ulcerans infection.
DISCUSSION
The histopathology of BU lesions in patients infected with
M. ulcerans has been characterized by a description of minimal
or absent cellular inflammation (1, 9, 11, 12, 22, 31–33, 35–37,
40, 41, 56, 65, 75), in contrast with what is known to occur in
response to infections by other pathogenic mycobacteria (6, 10,
14, 19, 47, 55, 62, 70, 71, 74, 85). Such a histopathological
hallmark has been associated with the M. ulcerans toxin my-
colactone that, among other effects, inhibits in vitro the
production by activated macrophages of the proinflamma-
tory cytokine TNF (13, 60). However, recent publications have
demonstrated that M. ulcerans induces cellular inflammatory
responses in specific areas of infection foci, both in BU pa-
tients (38) and in experimentally infected mice (59), with per-
sistence of recruited phagocytes at the periphery of mycolac-
tone-induced necrotic acellular areas (59, 84). These data
suggest that infection with viable M. ulcerans organisms in-
duces the production of cytokines and/or chemokines respon-
sible for the recruitment and, possibly, activation of inflammatory
cells.
In the present work we show that the levels of TNF produc-
tion by BMDM infected with different strains of M. ulcerans
are dependent on the cytotoxicity/virulence of the strain. Pro-
duction of TNF by macrophages was low, intermediate, or high
when they were infected with high, intermediate, or noncyto-
toxic/nonvirulent strains, respectively. The decreased produc-
tion of TNF by BMDM infected with highly cytotoxic/virulent
strains of M. ulcerans is not associated with a premature death
of macrophages in culture. Indeed, that production was quite
scant from the early time points of infection with these strains,
as well as in macrophage cultures infected with low MOIs that
did not induce cytotoxicity. Macrophages infected with the
highly virulent strains can, however, produce relevant amounts
of MIP-2, and the addition of mycolactone to cell cultures
infected with a mycolactone-defective strain does not abrogate
MIP-2 production. These results indicate that the decreased
production of TNF during intracellular infection with M. ul-
cerans is not due to a general toxic effect of mycolactone.
MIP-2 is the murine homologue of human IL-8 and plays a
central role in the recruitment of neutrophils in mice (27, 88).
This chemokine was previously shown to be induced in mice
infected with M. tuberculosis (68). Recently, the expression of
IL-8 was also reported in the lesions of patients infected with
M. ulcerans (64). The expression of this chemokine in BU
lesions is in accordance with the results from Guarner et al.
(38) and our own results (84) describing inflammatory infil-
trates containing neutrophils in the majority of the BU speci-
mens studied. Coutanceau and coworkers recently showed that
a mycolactone-producing strain of M. ulcerans induces expres-
sion of MIP-2 in infected macrophages (13). These and our
present results explain the occurrence of persistent inflamma-
tory infiltrates containing neutrophils in mice experimentally
infected with virulent strains of M. ulcerans (13, 59). In addi-
tion, it cannot be excluded that dead M. ulcerans, or bacilli not
producing mycolactone, may stimulate MIP-2 production and
contribute to the inflammatory response.
Our findings on the levels of virulence for mice, as well as on
the cytotoxic activity for infected macrophages, among M. ul-
cerans organisms that are mycolactone A/B or mycolactone C
producers are in accordance with previous reports showing a
higher cytotoxic effect of purified mycolactone A/B compared
to mycolactone C (56). It is clear from our data that the
outcome of infection by a particular M. ulcerans strain depends
on the type of mycolactone secreted by the pathogen. How-
ever, other factors contributing to the mycolactone-dependent
virulence of M. ulcerans cannot be discarded, namely, differ-
ences in the amount of toxin produced by each strain and even
FIG. 6. Proliferation of the mycolactone A/B-producing strain 98-912, mycolactone C-producing strain 94-1327, or mycolactone-negative strain
5114 in wild-type and TNF receptor-deficient mice. Mice (WT [closed symbols] or TNF-P55 KO [open symbols]) were infected subcutaneously in
the left hind footpad with 5.3 log10 AFB of M. ulcerans 5114 (diamonds), 94-1327 (triangles), or 98-912 (squares). The number of AFB in
homogenates from four footpads in each infected group was counted at the indicated time points. WT mice control the proliferation of M. ulcerans
5114 but do not eliminate the infection, whereas TNF-P55 KO mice are more susceptible to this strain. An increase in bacterial counts was also
found in the footpads of TNF-P55 KO mice infected with strain 94-1327 compared with the WT mice. No significant differences were found for
mice infected with M. ulcerans 98-912. For ethical reasons, mice were sacrificed after the emergence of ulceration. Statistical differences were
determined by comparing TNF-P55 KO mice with WT mice. Calculations were performed using Student’s t test. , P  0.05; , P  0.01; ,
P  0.001. Results are from one representative experiment out of two independent experiments.
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the possible regulation of toxin production that could be
switched on/off during defined periods of the pathogen’s life
cycle in the host, as previously discussed (84). In addition, the
possible existence of other M. ulcerans virulence factors cannot
be discarded. Further work is therefore necessary to elucidate
the causes for the variability in virulence found among M.
ulcerans strains.
As discussed above, the association between the mycolac-
tone profile and virulence in mice correlates inversely with the
capacity of M. ulcerans-infected BMDM to produce TNF. De-
creased production of TNF in response to virulent mycobac-
teria has been previously reported (28, 69). It is known, for
instance, that virulent M. tuberculosis H37Rv inhibits the pro-
duction of TNF by infected macrophages to a higher extent
than the nonvirulent strain H37Ra (23). However, the mech-
anisms for the decreased TNF production by these mycobac-
terial species are still unknown.
M. ulcerans is the only Mycobacterium known to produce a
cytotoxic exotoxin capable of inhibiting IL-2 and TNF produc-
tion from phorbol myristate acetate-ionomycin-activated T-cell
lines and lipopolysaccharide-activated human monocytes, re-
spectively (60). In the present work, we expand these observa-
tions by using a model of infection of primary macrophages
with live bacteria from a panel of M. ulcerans strains that
produce different amounts and types of mycolactone and that
exhibit diverse degrees of virulence for mice. The capacity of
virulent, mycolactone-producing M. ulcerans strains to down-
regulate the production of TNF might have consequences for
the outcome of infection, given that it has recently been
showed that M. ulcerans has a phase of intramacrophage res-
idence and proliferation (84). In fact, mice deficient in TNF or
in its P55 receptor are very susceptible to M. tuberculosis in-
fections (4, 26). From studies in the mouse model, it is known
that TNF is required to upregulate the macrophage bacteri-
cidal mechanisms, particularly in concert with IFN- (7, 24,
52). Our present data demonstrate that in experimental M.
ulcerans infection, the production of TNF also plays a protec-
tive role. By inhibiting the production of the macrophage-
activating cytokine TNF, virulent M. ulcerans strains would be
protected from the microbicidal mechanisms of macrophages,
allowing an extended time of intracellular proliferation until a
significant bacterial load is achieved.
The present and previous results (13, 60) show that myco-
lactone has an inhibitory activity on cytokine production in
vitro. It is still not clear whether this is an early manifestation
of impending cell death or a specific suppression of cytokine
production. Adusumilli and coworkers recently showed that
very low concentrations of mycolactone induce apoptosis in a
culture cell line (2). However, more studies are required to
address this question in vivo. The presence of TNF in the
lesions of BU patients has been inferred by the detection of
mRNA for this cytokine in samples of nonulcerative and ul-
cerative lesions (63, 64, 66), although a high variability in TNF
message has been detected in different patients (64, 66) as well
as in different areas within the same lesion (63).
These results show that production of TNF in BU lesions
can occur despite the presence of mycolactone, which may be
associated with bacilli or free in specific areas of the lesions. In
this context it is relevant to take into consideration that the
spatial relationship of TNF with the cytological pattern in
specific areas of a BU lesion, namely, the presence of macro-
phages and M. ulcerans bacilli, is still not clear (63). We can
hypothesize that TNF would be produced in BU lesions by (i)
macrophages infected with M. ulcerans bacilli in which myco-
lactone production would be temporarily switched off, (ii) mac-
rophages or other cell types distant from mycolactone-produc-
ing bacilli in areas not reached by the toxin but in contact with
mycobacterial molecules, and (iii) macrophages or other cell
types activated by proinflammatory molecules derived from the
process of tissue necrosis, regardless of the contact with M.
ulcerans or M. ulcerans-derived molecules.
It has been reported that the process of healing of necrotic
ulcers is associated with a granulomatous histopathology (1,
40, 41, 78, 86) and, in contrast, that disseminated disease and
osteomyelitis are associated with defects in granuloma forma-
tion (42, 78). It is well known that TNF has an important role
in the development and maintenance of the granuloma, a key
structure that prevents mycobacterial dissemination (4, 21, 26,
30, 48). The recently reported positive correlation between the
expression of proinflammatory cytokines, including TNF, and
the formation of granulomas in BU lesions (64) supports our
interpretation that TNF plays a protective role in M. ulcerans
infections and that a mycolactone-associated decreased pro-
duction of that cytokine would occur in the active phase of the
infection.
In conclusion, the data presented here show that macro-
phages infected with virulent, mycolactone-positive strains of
M. ulcerans produce amounts of the macrophage-activating
cytokine TNF that depend on the strain’s toxigenesis and that
this cytokine contributes to the protection of the infected host
against experimental M. ulcerans infection.
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